The EPA for Metastasis Trial 2 (EMT2) study protocol aims to address the need for safe and cost-effective adjunctive treatment for advanced colorectal cancer (CRC). The trial evaluates the effect of EPA on CRC outcomes in patients undergoing liver resection surgery for CRC liver metastasis. The primary endpoint is CRC progression-free survival, with key secondary endpoints being overall survival, safety, and tolerability of EPA. The study plans to publish full trial results in 2026, with subsequent publications of secondary analyses and translational work.
Journal Article by Hull MA, Ow PL (…) Toogood GJ et 16 al. in BMJ Open
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.